Fast Five Quiz: Progression of Follicular Lymphoma

Emmanuel C. Besa, MD


November 10, 2021

Figure 1. Illustration showing a field of lymph nodes connected by multiple lymphatic vessels; the node in cross-section shows the gross pathology of follicular lymphoma breaking through the node capsule.

Progression or relapse of FL within 2 years after diagnosis (a phenomenon known as POD24) is associated with a poor outcome for patients treated with R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone).

Although many patients with FL have an indolent, relapsing-remitting disease course, as well as a favorable prognosis, approximately 20% experience early disease progression after initial treatment with chemoimmunotherapy. Patients with POD24 are enriched for mutations in KMT2C, TP53, BTG1, MKI67, XBP1, SOCS1, IKZF3, B2M, FAS, and MYD88.

Learn more about the practice essentials of FL.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.